GlassScriptPhysician profile
James C Sheppard
NPI 1528075835
$3,603.48
in general payments reported to CMS, 2019-2025
38 companies · $872 in 2025
The $872 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $289 · 2021: $555 · 2022: $545 · 2023: $370 · 2024: $669 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,910 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,910.34 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $653.01 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $563.42 | 2021-2025 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $395.76 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $262.06 | 2019-2025 | |
| Glaxosmithkline, LLC. | $181.33 | 2019-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $170.54 | 2021-2025 | |
| Lilly USA, LLC | $154.66 | 2020-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $113.12 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $110.65 | 2022-2024 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.29 | 2021-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $61.33 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $57.22 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.60 | 2024-2025 | Caplyta |
| Verona Pharma, INC. | $47.22 | 2025 | Ohtuvayre |
| Abbott Laboratories | $46.32 | 2021-2024 | Eterna |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sheppard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.